Curated dataset · n=61 verified deals · Not live market data · Scores are descriptive, not forecasts.
You are here

Deals — Network graph, deal flow, valuation matrix, and acquirer landscape.

Eugin Group (North American operations)
→
KKR (via IVI-RMA)

Acquisition · Cash · announced Nov 1, 2023

View in network
  1. Announced

    Nov 1, 2023

  2. Closed

    Jan 31, 2024

Economics

Cash()

Pre-deal · pre-deal mark: 2023, year precision · rounding grid ±$100M · IVI-RMA Global press release — Eugin Group acquisition, 2024

Part of KKR/GED Capital €494M (~$534M) acquisition of Eugin from Fresenius; this covers Boston IVF and TRIO

Target

Eugin Group (North American operations)

Fertility · Fertility science

HQ Barcelona, Spain · Founded 1999

Global fertility network including Boston IVF and TRIO (Toronto); 13 labs and 32 satellite offices in North America

  • Business Wire - IVI RMA completion announcement (January 31, 2024)
  • PitchBook (November 2023) - deal reporting
  • Fresenius SE press release (divestiture)

Acquirer

KKR

Healthcare

HQ New York, NY

Global investment firm; major investor in fertility clinic consolidation

Why this buyer

Curated copy from the verified dataset — not an 8-K LLM summary

Added Boston IVF (Harvard-affiliated, 13 labs) and TRIO (Toronto) to IVI-RMA network, consolidating North American fertility market leadership

Evidence ladder

Press only — no primary filingValue disclosed
  1. Secondary (press / IR)

    Business Wire (January 31, 2024)

  2. Tertiary (trade / analyst)

    PitchBook (November 2023)

Limitations

  • Citations are press/IR only — two wires of the same announcement are not dual-source. Add a primary filing.
  • Part of KKR/GED Capital €494M (~$534M) acquisition of Eugin from Fresenius; this covers Boston IVF and TRIO
  • Pre-deal valuation sourced from: IVI-RMA Global press release — Eugin Group acquisition, 2024. Pre-deal market-cap and funding citations do not corroborate the acquisition.

Valuation peers · Fertility

Same sector, same deal type, announced within ±3 years, disclosed value within 0.25×–4× of this transaction. Ranked by evidence class, then same acquirer, until you sort.

Why included
Indira IVFBPEA EQTJul 28, 2023same evidence class
Hamilton ThorneAstorgJul 22, 2024same evidence class
Modern FertilityRoMay 19, 2021value band

Same-sector adjacency — not valuation peers

These deals share the sector tag and window but sit outside the 0.25×–4× value band. The dataset keeps them for clinical adjacency, not as price comps.

Vs this deal
IVI-RMA GlobalKKRMar 1, 2022

Other verified deals by KKR

Acquirer program history not already listed as a valuation peer or adjacency row.

No further verified deals

Other verified transactions by KKR are already listed above, or none are in the dataset.

Patient empowerment context

Patient empowerment baseline (HLTH 2022)

No curated mapping — Eugin Group (North American operations) (Fertility). HLTH/Outcomes4Me 2022 baseline is Breast cancer care continuum (HLTH 2022). No curated mapping for this target in the verified crosswalk.

Research workspace (includes heuristic crosswalk) →

Related verified workspaces

Lacuna is a curated public-source sample, not a census of women's-health M&A. Coverage varies by sector, geography, disclosure availability, and women's-health scope. Undisclosed transaction values are excluded from disclosed-value totals.

Curated verified dataset v11 · updated 2026-10-19 · 2 citations on this deal · Data compiled from public sources for educational visualization. Verify independently before any commercial use.